RhumbLine Advisers’s Standard BioTools LAB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $81K | Sell |
98,378
-266,511
| -73% | -$252K | ﹤0.01% | 3597 |
|
|
2026
Q1 | $335K | Sell |
364,889
-9,590
| -3% | -$11.6K | ﹤0.01% | 2859 |
|
|
2025
Q4 | $479K | Sell |
374,479
-46,135
| -11% | -$62K | ﹤0.01% | 2686 |
|
|
2025
Q3 | $547K | Sell |
420,614
-52,367
| -11% | -$68.6K | ﹤0.01% | 2639 |
|
|
2025
Q2 | $568K | Buy |
472,981
+60,220
| +15% | +$66.8K | ﹤0.01% | 2606 |
|
|
2025
Q1 | $446K | Buy |
412,761
+42,247
| +11% | +$59.3K | ﹤0.01% | 2647 |
|
|
2024
Q4 | $648K | Sell |
370,514
-10,975
| -3% | -$20.4K | ﹤0.01% | 2495 |
|
|
2024
Q3 | $736K | Sell |
381,489
-25,978
| -6% | -$50.9K | ﹤0.01% | 2438 |
|
|
2024
Q2 | $721K | Buy |
407,467
+396,719
| +3,691% | +$970K | ﹤0.01% | 2426 |
|
|
2024
Q1 | $29.1K | Buy |
10,748
+7,857
| +272% | +$19K | ﹤0.01% | 3714 |
|
|
2023
Q4 | $6.39K | Hold |
2,891
| – | – | ﹤0.01% | 3937 |
|
|
2023
Q3 | $8.38K | Hold |
2,891
| – | – | ﹤0.01% | 3898 |
|
|
2023
Q2 | $5.58K | Buy |
+2,891
| New | +$5.71K | ﹤0.01% | 4064 |
|
|
2022
Q2 | – | Sell |
-96,009
| Closed | -$345K | – | 3175 |
|
|
2022
Q1 | $345K | Sell |
96,009
-8,203
| -8% | -$28.3K | ﹤0.01% | 2594 |
|
|
2021
Q4 | $409K | Sell |
104,212
-1,315
| -1% | -$6.16K | ﹤0.01% | 2589 |
|
|
2021
Q3 | $695K | Buy |
105,527
+2,435
| +2% | +$16K | ﹤0.01% | 2399 |
|
|
2021
Q2 | $635K | Sell |
103,092
-10,201
| -9% | -$54.5K | ﹤0.01% | 2447 |
|
|
2021
Q1 | $512K | Sell |
113,293
-4,260
| -4% | -$23.4K | ﹤0.01% | 2480 |
|
|
2020
Q4 | $705K | Buy |
117,553
+15,194
| +15% | +$99.8K | ﹤0.01% | 2289 |
|
|
2020
Q3 | $761K | Sell |
102,359
-16,300
| -14% | -$113K | ﹤0.01% | 2095 |
|
|
2020
Q2 | $476K | Buy |
118,659
+35,494
| +43% | +$124K | ﹤0.01% | 2367 |
|
|
2020
Q1 | $211K | Sell |
83,165
-656
| -0.8% | -$2.15K | ﹤0.01% | 2560 |
|
|
2019
Q4 | $292K | Sell |
83,821
-225
| -0.3% | -$791 | ﹤0.01% | 2604 |
|
|
2019
Q3 | $389K | Sell |
84,046
-44
| -0.1% | -$347 | ﹤0.01% | 2435 |
|
|
2019
Q2 | $1.04M | Buy |
84,090
+43,507
| +107% | +$554K | ﹤0.01% | 2055 |
|
|
2019
Q1 | $539K | Buy |
40,583
+6,094
| +18% | +$64.2K | ﹤0.01% | 2303 |
|
|
2018
Q4 | $297K | Buy |
34,489
+10,358
| +43% | +$80.7K | ﹤0.01% | 2549 |
|
|
2018
Q3 | $181K | Sell |
24,131
-1,625
| -6% | -$11.6K | ﹤0.01% | 2759 |
|
|
2018
Q2 | $154K | Sell |
25,756
-7,690
| -23% | -$43.8K | ﹤0.01% | 2798 |
|
|
2018
Q1 | $195K | Buy |
33,446
+5,505
| +20% | +$36.1K | ﹤0.01% | 2612 |
|
|
2017
Q4 | $165K | Sell |
27,941
-3,248
| -10% | -$17.8K | ﹤0.01% | 2681 |
|
|
2017
Q3 | $157K | Buy |
31,189
+720
| +2% | +$3.03K | ﹤0.01% | 2811 |
|
|
2017
Q2 | $123K | Sell |
30,469
-1,733
| -5% | -$8.22K | ﹤0.01% | 2876 |
|
|
2017
Q1 | $183K | Buy |
32,202
+1,362
| +4% | +$8.63K | ﹤0.01% | 2672 |
|
|
2016
Q4 | $225K | Sell |
30,840
-2,557
| -8% | -$16.1K | ﹤0.01% | 2626 |
|
|
2016
Q3 | $268K | Buy |
33,397
+360
| +1% | +$3.31K | ﹤0.01% | 2538 |
|
|
2016
Q2 | $298K | Buy |
33,037
+5,331
| +19% | +$50.1K | ﹤0.01% | 2537 |
|
|
2016
Q1 | $224K | Buy |
27,706
+100
| +0.4% | +$721 | ﹤0.01% | 2680 |
|
|
2015
Q4 | $298K | Buy |
27,606
+2,110
| +8% | +$20.7K | ﹤0.01% | 2584 |
|
|
2015
Q3 | $207K | Buy |
25,496
+881
| +4% | +$13.9K | ﹤0.01% | 2772 |
|
|
2015
Q2 | $596K | Sell |
24,615
-1,560
| -6% | -$49.2K | ﹤0.01% | 2215 |
|
|
2015
Q1 | $1.1M | Buy |
26,175
+4,250
| +19% | +$168K | ﹤0.01% | 1796 |
|
|
2014
Q4 | $740K | Sell |
21,925
-525
| -2% | -$14.9K | ﹤0.01% | 2006 |
|
|
2014
Q3 | $550K | Sell |
22,450
-100
| -0.4% | -$2.81K | ﹤0.01% | 2148 |
|
|
2014
Q2 | $663K | Buy |
22,550
+1,539
| +7% | +$49.3K | ﹤0.01% | 2090 |
|
|
2014
Q1 | $926K | Sell |
21,011
-1,650
| -7% | -$72.6K | ﹤0.01% | 1854 |
|
|
2013
Q4 | $868K | Buy |
22,661
+150
| +0.7% | +$4.42K | ﹤0.01% | 1915 |
|
|
2013
Q3 | $494K | Sell |
22,511
-223
| -1% | -$4.38K | ﹤0.01% | 2216 |
|
|
2013
Q2 | $397K | Buy |
+22,734
| New | +$399K | ﹤0.01% | 2432 |
|
Other funds holding LAB
CC
MCO
LFCM
HBWM
RA
RhumbLine Advisers's LAB Position: Q2 2026 in Review
RhumbLine Advisers reduced its Standard BioTools (LAB) stake by 73% in Q2 2026, selling an estimated $252K and leaving 98,378 shares worth $81K. The position accounts for ﹤0.01% of the portfolio, ranked #3597.
RhumbLine Advisers first reported a position in LAB in Q2 2013 and has held it in 49 quarters since. The position peaked at $1.1M in Q1 2015. 144 funds tracked by Wall St. Rank hold LAB as of Q2 2026.
- RhumbLine Advisers held 98,378 shares of Standard BioTools worth $81K as of Q2 2026.
- RhumbLine Advisers sold 266,511 Standard BioTools shares in Q2 2026, an estimated $252K.
- Standard BioTools made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3597 holding.
- RhumbLine Advisers first reported a position in Standard BioTools in Q2 2013 and has held it in 49 quarters since.
- RhumbLine Advisers's Standard BioTools position peaked at $1.1M in Q1 2015.
- 144 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.
Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.